JPRN-UMIN000022861已完成未知
Phase I trial of capecitabine, oxaliplatin and irinotecan combination chemotherapy (XELOXIRI) for advanced gastric cancer - Phase I trial of XELOXIRI for advanced gastric cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) HER2 positive 2) UGT1A1 *6 or *28 homozygote or *6 and *28 heterozygote 3) Symptomatic brain metastasis 4) Infectious disease 5) Grade 2 or more diarrhea 6) Grade 2 or more peripheral sensory neuropathy 7) Massive pleural effusion, ascites, or cardiac effusion 8) Ileus 9) Defined interstitial pneumonia
研究者
相似试验
已完成
1 期
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaPancreatic NeoplasmsBile Duct NeoplasmsNCT00634751University of Wisconsin, Madison48
招募中
2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000039783Sapporo Medical University School of Medicine47
进行中（未招募）
不适用
Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer - BOXERMetastatic colorectal adenocarcinoma with metastases involving the liver onlyMedDRA version: 8.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2005-004505-29-GBRoyal Marsden NHS Trust46
Unknown
不适用
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01311050King Faisal Specialist Hospital & Research Center46
已完成
1 期
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By SurgeryUnspecified Adult Solid Tumor, Protocol SpecificNCT00043121National Cancer Institute (NCI)50